Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

Source

World

These companies have earnings momentum heading into their quarterly reports next week

January 24, 2025

Some companies reporting earnings next week have forward earnings momentum that investors may be able to ride. Next week will be busy for fourth-quarter earnings, with 90 companies in the S & P 500 index — and eight members of the Dow Jones Industrial Average — on the docket to report quarterly results. With companies […]

World

Russia’s Putin says he and Trump should meet to talk about Ukraine war, energy prices

January 24, 2025

Russian President Vladimir Putin winks during his annual televised year-end press conference and phone-in held in Moscow, Russia December 19, 2024. Maxim Shemetov | Reuters Russian President Vladimir Putin said on Friday he was open to discussions with U.S. President Donald Trump on issues such as the Ukraine war and energy prices, and said it […]

World

UK to soften tax rules for wealthy foreigners after millionaire exodus, Rachel Reeves says

January 24, 2025

Rachel Reeves, UK Finance Minister, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 22, 2025. Gerry Miller | CNBC The U.K. will soften some planned changes to its controversial non-dom tax rule following concerns of a millionaire exodus, the Treasury has confirmed. Britain’s 200-year-old non-dom regime permits people […]